Theme: Advanced Research and innovative Therapeutics Approaches towards Pulmonary Disorders

Pulmonary Disorders 2017

Pulmonary Disorders 2017

Sessions/Tracks

Conference series LLC cordially welcomes you all to attend and participate at the International Conference on Pulmonary Disorders during April 24-25, 2017 Las Vegas, USA.

Theme: Advanced Research and innovative Therapeutics Approaches towards Pulmonary Disorders

Pulmonary Disorders 2017 includes prompt keynote presentations, Oral talks, Poster presentations, B2B meetings, Symposia and Exhibitions.

The goal of Pulmonary Disorders 2017 is to bring together bright minds to give talks that are idea focused, and on a wide range of subjects in respiratory Disorders, Lungs Disease and Pulmonary Disorders to foster learning, inspiration; wonder and research provoke conversations that matter.

Track 1: Pulmonary Diseases and Disorders
Pulmonary Disorders is the abnormal conditions of the respiratory system. Abnormal Conditions includes; chest pain, cough, sputum production, dyspnea, hemoptysis, adventitious sounds and stridor. Pulmonary Disorders is often caused by the decrease or compression of air flow paths that impedes air flows in lungs or respiratory system pathways. People with Pulmonary Disorders could have acute respiratory failures, like general anesthesia or infections. There are numbers of Pulmonary Disorders which need to be studied individually as their caused; condition and symptoms are different from each other’s. It has been found that the most common pulmonary cause of acute respiratory failure is due acute restrictive.

Related: Pulmonary Disorders Conferences | Pulmonary Congress Pulmonary Disease Events | Critical Care Medicine Conference:
2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, European  Lung FoundationNational Institutes of Health (NIH), American Lung AssociationCanadian Lung AssociationEuropean Respiratory Society

Track 2: Symptoms and Comorbids
The full form of COPD is chronic obstructive pulmonary disease and this name includes number of pulmonary disease and conditions like chronic bronchitis and emphysema. Its symptoms are usually slow developing symptoms and it shows over a number of time periods or years. Hence, the effected peoples are often not in aware of having this disease.

The people having COPD will be characterized with swelled lungs and narrow respiratory tracks. Thus, the air sacs in lungs get damaged permanently and it cause severe problems in breathing.
Till there is no cure for COPD completely, therefore, sooner the disease is examined and diagnosed and appropriate treatment like; pulmonary rehabilitation is practiced in order to let less damage to the lungs.

Related: Pulmonary conference Pulmonary Congress Pulmonary Disease conference Critical Care Medicine Conference:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, New York Society for Respiratory Care, South Carolina Society for Respiratory Care , Utah Society for Respiratory Care,West Virginia Society for Respiratory CareVirginia Society for Respiratory Care

Track 3: Pulmonary Function Testing
A broad range of test which measures the status of wellness of lungs functions and property to exhale and inhale air and the efficiency as well as capability of lungs in transferring Oxygen into blood is collectively known as Pulmonary Function Testing.
The process includes the chest x-ray and physical examinations. Its outcomes often suggest what additional testing may be needed to determine what is causing the person's symptoms and disease. This test includes predominant practice of measuring the lung’s capacity to move and hold air and to exchange oxygen and carbon dioxide in connective tissues of the body. There are other severe complications for which these test not that enough. So, in such case, special and sophisticated test systems are used, which includes; Thoracoscopy, Imaging, Echocardiography, Ultrasound Procedures and Bronchoscopy.  These allow examiners to determine the specific causes lungs disorders or pulmonary disorders.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine Conference:
4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Texas Society for Respiratory CareSouth Carolina Society for Respiratory CareWashington: Respiratory Care Society of Washington, IncWyoming Society for Respiratory Care , Idaho Society for Respiratory Care

Track 4: Acute Bronchitis
Acute bronchitis is a common respiratory disease which is caused by the infection of bronchi with germs or virus.  Infection with virus is more common than infection with germ or bacteria.Like other pulmonary disorders, acute bronchitis is inflammation of the trachea or windpipe. These wind pipes roles are to deliver airs to the lungs and other connective tissues.
Very often, people do mistakes by assuming chronic bronchitis as acute bronchitis. Hence, it is crucial to distinguish chronic bronchitis from acute bronchitis. However, these diseases normally last for less than a week. But, the cough remain continue for several days and weeks after the inflammation get healed. Till now, it has been reported that the viruses that cause flu and colds also causes acute bronchitis. Acute bronchitis is a communicable disease. It is the viruses which spread through the air when people do physical and cough.  Most vulnerable to these diseases are in being exposed to polluted air and smoke, vapours and dust, fumes can also be a responsible for causing this disease.

Related: Pulmonary Disorders ConferencesPulmonary Congress Pulmonary Disease Events | Critical Care Medicine:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Asia Pacific, SydneyBritish Thoracic SocietyEuropean Lung FoundationNational Institutes of HealthAmerican Lung Association,American Association of Respiratory Care

Track 5: Asthma and Related Disorders
Asthma is a disease characterized by inflammation, swelling, narrowness and production of extra mucus in the airways of person’s respiratory tracks. It is caused by different types of allergens. Allergens trigger the bronchoconstriction process resulting in difficulties of air passage.  Asthma patients experience chest tightness, cough which is a common in all asthma patients, dyspneawheezing and chest tightness.

Many other disorders have been recognised to show similar sign and symptoms like asthma does. Hence, just because y we have symptoms and sign of asthma, does not mean that we have this diseases. Other related disorders to asthma include; Sinusitis, Myocardial ischemia, and Gastroesophageal reflux disease (GERD). Some other severe disease like asthma includes chronic obstructive pulmonary disease (COPD), chronic obstructive pulmonary disease (COPD), and Bronchogenic carcinoma.  Congestive heart failure, Bronchiectasis and Respiratory syncytial virus (RSV) also shows symptoms like asthma.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine conference:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Canadian Lung Association,European Respiratory SocietyJapanese Respiratory SocietyNational Lung Health Education ProgramAsian Pacific Society of Respirology

Track 6: Bronchiectasis and Atelectasis
An irreversible widening of the breathing pipes or respiratory airways resulting from damage to the cilia of epidermal is called Bronchiectasis. The severity of bronchiectasis is tested by computed tomography, Chest x-rays and breathing test. People often are given antibiotics and use other measures to suppress and clear the build-up of mucus.  The conditions in which lungs collapse and became airless are called atelectasis.
The most common cause of atelectasis is blockage of the bronchial tubesAtelectasis decreases the level of oxygen in the blood. This is caused due to alveoli closed and thus, stops gas exchanges between blood and alveoli.

Related: Pulmonary Disorders ConferencesPulmonary Congress Pulmonary Disease Events | Critical Care Medicine:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Alabama Society for Respiratory CareBritish Columbia Society of Respiratory TherapistsKansas Respiratory Care Society, Missouri Society for Respiratory Care,Nevada Society for Respiratory Care

Track 7: COPD and Related Disorders
Chronic obstructive lung disease (COPD) is not a single type of respiratory diseases. It is a combination of groups of lungs disease that caused difficult to breath out gas from the lungs. Thus, it often leads to feeling of being tired or shortness of breath.  COPD are often categorised into two major symptoms i.e. emphysema and chronic bronchitis. So, a person having COPD may be facing either chronic bronchitis or emphysema.
COPD symptoms are productive cough and dyspnea. The common signs and symptoms include decreased breath prolonged expiratory phase of respirationwheezing and sounds.  COPD get severe and may cause pneumothorax, weight loss, frequent acute decompensation episodes and heart failure. It also causes respiratory failure and acute or chronic. It is diagnosis on history base, physical examination base, pulmonary function tests and chest x-ray.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, New York Society for Respiratory CareSouth Carolina Society for Respiratory Care , Utah Society for Respiratory CareWest Virginia Society for Respiratory CareVirginia Society for Respiratory Care

Track 8: Cardiovascular disease
Pulmonary vascular diseaseheart and blood vessel disease also known as the disease affaecting the blood vessels leading to lungs from heart, it includes number other diseases which are related to atherosclerosis process. Atherosclerosis is the build-up narrows the arteries condition that develops when a substance called plaque builds up in the walls of the arteries in the connected with the heart. , it includes number other diseases which are related to atherosclerosis process. Atherosclerosis is the build-up narrows the arteries condition that develops when a substance called plaque builds up in the walls of the arteries in the connected with the heart. This cause stroke and heart attack by the blocking of arteries to stops blood flow.  Blocking of the effected arteries is often due to blood clotting inside the arteries.

Related: Pulmonary Disorders ConferencesPulmonary Coference Pulmonary Disease Events | Critical Care Medicine:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Asia Pacific, SydneyBritish Thoracic SocietyEuropean Lung FoundationNational Institutes of HealthAmerican Lung Association,American Association of Respiratory Care

Track 9: Diffuse Alveolar Hemorrhage
Diffuse alveolar hemorrhage (DAH) refers to hemorrhage which originates in the pulmonary microvasculature. It is a life threatening respiratory disease. The clinical syndrome of alveolar hemmorrhage is characterized by diffuse pulmonary infiltrates, hypoxemic respiratory failure, falling haematocrit and hemoptysis.
People with alveolar hemorrhage face dyspnea, hemoptysis and cough. The diagnosis and physical exam are quite nonspecific.  Pateinst will make a rapid succession on their pulmonary test. The test needs careful attention to oropharyngeal exam and to the nasal to exclude clues to a collagen vascular disease or vasculitis.

Related: Pulmonary Disorders ConferencesPulmonary Congress Pulmonary Disease Events | Critical Care Medicine:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Alabama Society for Respiratory CareBritish Columbia Society of Respiratory TherapistsKansas Respiratory Care SocietyMissouri Society for Respiratory CareNevada Society for Respiratory Care

Track 10: Environmental Pulmonary Diseases
Environmental pulmonary diseases are caused by inhalation of allergens, dusts, chemicals, environmental pollutants and gases. Thus, it is known for a risk factor for asthma, it is also being recognized as a cause of COPD in non-smoking person.
A patient who has used a respiratory protection device such as masks, quality respirators and non- smoker has been well protected from the Environmental Pulmonary Diseases.  A patient with Environmental Pulmonary Diseases must go through medical surveillance. Medical surveillance is a form of secondary prevention.

Related: Pulmonary Disorders ConferencesPulmonary Congress Pulmonary Disease Events | Critical Care Medicine:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Alabama Society for Respiratory CareBritish Columbia Society of Respiratory TherapistsKansas Respiratory Care Society, Missouri Society for Respiratory Care,Nevada Society for Respiratory Care

Track 11: Lung Diseases
Lung disease is any problem in the lungs that prevents the lungs from working properly. Lungs diseases are categorised into three main types i.e. Lung tissue diseases, Airway diseases and Lung circulation diseases. Airway diseases affect the airways that carry oxygen and other gases into and out of the lungs in the body. They usually cause a narrowing or blockage of the airways. Airway diseases include asthma, emphysema, bronchiectasis, and chronic bronchitis.

Lung tissue diseases affect the tissue of the lung.  Inflammation of the tissue makes the lungs unable to constrict and expand fully. Thus, it became hard for the lungs to release carbon dioxide and take in oxygen.  Examples of lung tissue disease are pulmonary fibrosis and sarcoidosis.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, New York Society for Respiratory Care, South Carolina Society for Respiratory Care , Utah Society for Respiratory Care,West Virginia Society for Respiratory CareVirginia Society for Respiratory Care

Track 12: Pleural Effusion
Pleural Effusion is disease causing to increase an abnormal amount of fluid around the lungs i.e. in a thin membrane that lines the surface of the lungs and the inside of the chest wall outside the lungs. Fluid accumulates in the space between the layers of pleura which allows the lungs to move smoothly within the chest cavity during exhaling and inhaling air. Pleural effusions are result many other medical contortions. It has been noted that, most pleural effusions are not so serious; however, they need immediate treatment to avoid problems which can be severe respiratory diseases.

The heart, kidney and liver disease may cause excessive fluid to accumulate around the lungs. It may be because the body loss its property of handling fluids. The fluid in pleural effusions may from inflammation and damage, such as in autoimmune disease, pneumonia, and many other related disorders. In Pleural Effusions, it is hard to determine particular symptom for pleural effusion disease. Because pleural effusions are usually caused by many underlying medical conditions or disease, the symptoms of these conditions are also often known.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine:
4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Texas Society for Respiratory CareSouth Carolina Society for Respiratory CareWashington: Respiratory Care Society of Washington, IncWyoming Society for Respiratory Care , Idaho Society for Respiratory Care

Track 13: Pulmonary Embolism
A disease which cause blockage of blood vessels, pulmonary artery and blood vessels are known as pulmonary embolism. Like Pleural Effusionpulmonary embolism symptoms are also difficult to recognise as they are vary from person to person. Common symptoms include; chest pain which is like stabbing pain that may be worse when you breathe in. Shortness of breath developed gradually or comes suddenly.  Coughing, is usually dry, but may include blood in mucus. The blood in our body travels from hearth to lungs and almost every part of our body.

Related: Pulmonary Disorders ConferencesPulmonary Congress Pulmonary Disease Events | Critical Care Medicine:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Canadian Lung Association,European Respiratory SocietyJapanese Respiratory SocietyNational Lung Health Education ProgramAsian Pacific Society of Respirology

Track 14: Sleep Apnea
Sleep apnea is a sleep disorder characterized by pauses in breathing or instances of shallow breathing.  Apnea is the pauses between breaths. It can last for a few seconds to several minutes i.e. often severe for the body.  And each abnormal shallow breathing event is termed as hypopneaSleep apnea has been categorised into three forms i.e. obstructive (OSA), mixed sleep apnea and central sleep apnea (CSA). If breathing is interrupted by a lack of respiratory effort then, it is called as CSA and if, breathing is interrupted by snoring or by physical block to airflow despite respiratory effort then, it is kwon as OSA.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Asia Pacific, SydneyBritish Thoracic SocietyEuropean Lung FoundationNational Institutes of HealthAmerican Lung Association,American Association of Respiratory Care

Track 15: Pulmonary Research
There is an urgent need of proper and innovative research on pulmonary disorders. It is because, between 3 and 7 million Americans are currently diagnosed with chronic obstructive pulmonary disease (COPD). These people suffer years of progressive discomfort and disability with their respiratory systems. With the number of deaths per year attributed to this disease at approximately 100,000 and increasing thus, COPD is now the fourth leading cause of death in this country and is expected to be third by the year 2020. Cigarette smoking is firmly established as the major cause of COPD, but approximately one-quarter of Americans continue to smoke, despite aggressive smoking prevention and cessation efforts. Better means are clearly needed for the prevention and treatment of COPD, and more scientific research is needed to enable improvements in its clinical management.

Research progress in pulmonary disorders has been slow and inappropriate. The main focus of the basic pulmonary research over the past 40 years has focused on the roles of inflammation, cigarette smoke, and the balance of protease.  However, now there are encouraging indications for future COPD and pulmonary disorders research. Furthermore, the detail study of several cellular pathways that are critically involved in COPD pathogenesis and respiratory disease may lead rapidly to clinical trials of potential therapeutics. Clinical trials have given the improving capabilities of the pharmaceutical industry for development of mechanism specific drugs for COPD and respiratory problems.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Canadian Lung Association,European Respiratory SocietyJapanese Respiratory SocietyNational Lung Health Education ProgramAsian Pacific Society of Respirology

Track 16: Pulmonary Rehabilitation
Pulmonary rehabilitation is a program of education, support and exercise to help the people to learn to breath and function at the highest level.  At pulmonary rehabilitation, people learn how to manage your COPD and to stay healthy.
At Pulmonary Rehabilitation, the rehabilitation team talks to the patient’s current level of activity and takes a complete health history. Thus, they set goals to help your for healthy breath and for what is most important. They monitor the patients’ blood pressure and oxygen level and heart beat rate.  At last patient often accomplished their healthy breathing system.  New and advance system has to get into practice in order to get quick heal in short time unlike the way classical rehabilitation system does heal.

Related: Pulmonary Disorders ConferencesPulmonary Congress Pulmonary Disease Events | Critical Care Medicine:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Alabama Society for Respiratory CareBritish Columbia Society of Respiratory TherapistsKansas Respiratory Care SocietyMissouri Society for Respiratory CareNevada Society for Respiratory Care

Track 17: Critical Care Medicine
Critical care medicine envelops the analysis and treatment of a wide assortment of clinical issues represent to the extreme of  human diseases. Critically sick patients require concentrated care by a planned group. The critical care expert might be the essential supplier of care or a specialist. The intensivist should be skilful not just in a wide scope of conditions normal among critically sick patients additionally with the mechanical systems and gadgets utilized as a part of escalated care settings. The care of critically sick patients additionally raises numerous confused moral and social issues, and the intensivist must be able in ranges, for example, end-of-life choices, propel mandates, evaluating visualization, and guiding of patients and their families.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine:
5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, 2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Alabama Society for Respiratory CareBritish Columbia Society of Respiratory TherapistsKansas Respiratory Care Society, Missouri Society for Respiratory Care,Nevada Society for Respiratory Care

Track 18: Novel Approach and Therapies
A novel approach is needed in the therapeutics strategy of dealing with air born disease and respiratory problems.  Lungs are exposed to number of airborne pathogen or toxic as it inhale and exhale more than 10,000 litres of air daily. This airway epithelium responds to such exposure by increasing its production of mediators such as cytokines, chemokines and antimicrobial peptides thus, it triggers or activates body immune system to defence pulmonary circulation of body. Recent findings indicate the importance of these peptides as effector molecules of innate immunity by killing microorganisms, but also as regulators of inflammation, immunity and wound repair. The clinical relevance of the functions of the airway epithelium in innate immunity is discussed and explained detail in many articles. Similarly, a novel approach in the therapeutics strategy is requiring dealing with all other respiratory and pulmonary disorders.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine Conference:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, New York Society for Respiratory CareSouth Carolina Society for Respiratory Care , Utah Society for Respiratory CareWest Virginia Society for Respiratory CareVirginia Society for Respiratory Care

Track 19: Technologies and Global Markets
In today’s economic climate your business decisions are as crucial as ever. International Conference on Pulmonology, Pulmonary & Critical Care Medicine allows you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services. International Conference on Pulmonology, Pulmonary & Critical Care Medicine is organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in.
Pulmonary Disorders 2017 organizing committee anticipates over 300 participants to attend this premier event. Your organization will benefit with excellent exposure to the leaders in Pulmonology.
Pulmonary Disorders 2017 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.
Participant will come to know about the how well their business is using the current marketing techniques. Business Participants will come to know about the progress and results of the past on pulmonary and respiratory market.
Pulmonary Disorders 2017 is also focuses on external and internal factors. Know about the strengths and weaknesses of the current business/company strategies and get clear vision about your business/company on its time and resource in a single platform at Pulmonary Disorders 2017.Get insight into current trends and understand your business, product, service as well as your competitors. Increase you network and take the advantages of B2B meetings at Pulmonary Disorders 2017.

Related: Pulmonary Disorders ConferencesPulmonary Conference Pulmonary Disease Events | Critical Care Medicine Conference:
2nd International Conference on Chest March 24-26, 2017 Melbourne, Australia, 5th International Conference & Exhibition On Lung & Respiratory Care May 8-10, 2017 Dubai, UAE, 2nd Respiratory & Pulmonary Medicine Conference Aug 6-8, 2017 London, UK, 4th Chronic Obstructive Pulmonary Disease May 29-31, 2017 Osaka, Japan, Respiratory Conditions - Essential Oils for Respiratory Conditions February 03 2017 London, United Kingdom, World Congress of Internal Medicine October 18-22, 2018 Cape Town, South Africa, 7th International American Oncology Conference October 05-06, 2017 Buenos Aires, Argentina, EMBL-Cancer Core Europe Conference: Cancer Immunotherapy February 02-04, 2017 Heidelberg, Germany, 7th International Symposium on cancers April 20-22, 2017 San Francisco, United States, Alabama Society for Respiratory CareBritish Columbia Society of Respiratory TherapistsKansas Respiratory Care SocietyMissouri Society for Respiratory CareNevada Society for Respiratory Care
 





About Conference

Conference Series LLC invites all the participants from all over the world to attend International Conference on Pulmonology, Pulmonary & Critical Care Medicine during April 24-25, 2017 in Las Vegas, the USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. 

Pulmonary Disorders 2017 Conference aims at gathering the audience from all the major parts of the World with a goal to enhance the scientific knowledge by exploring the latest advancements in the related conference field area. The conference will include explicit keynote and plenary sessions delivered by the distinguished researchers, scientists and honorary lecturers working in the field of pulmonary research & therapeutics. Pulmonary Disorders 2017 will encourage the participation of the eminent professors, researchers and students in all areas of lung disorder & therapeutics and will provide an international forum for the dissemination of original research results, new ideas and practical development experiences concentrating on the scientific development. Conferenceseries LLC organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in the USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contain over 30000 eminent personalities, reputed scientists as editorial board members. 

Why attend?

With members from around the world focused on learning about Pulmonary, Lung and Respiratory Disease and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pulmonary, Lung, and Respiratory community. Conduct presentations, distribute information, meet with current and potential scientists, this conference will encourage innovative ideas and advanced diagnostic approaches towards the pulmonary disorders. It will share recent advancements and knowledge share about the Pulmonary, Critical Care Medicine, Lung, and Respiratory treatment strategies. The participant companies can display their product to gain the networks and to promote their upcoming new strategies for the future era.

Target Audience:

  • Pulmonary, Lungs and Respiratory organization/department Directors/CEO
  • Pulmonary, Lung and Respiratory Research Scientists 
  • Pulmonologists, Respiratory Therapist & Pediatricians
  • Chest Physicians, Association presidents
  • Pulmonary, Lung and Respiratory Scholars, and Students
  • Pulmonary, Lung and Respiratory Care Associations
  • Pulmonary, Lungs and Respiratory Societies
  • Business Entrepreneurs
  • Thoracic surgeons, Radiologists
  • Medical and Nursing Students, Professors
  • Pharmaceutical companies
  • Manufacturing Medical Devices Companies
  • Respiratory practitioner
  • Physician
  • Respiratory Care Practitioner (RCP)
  • Respiratory scientist
  • Respiratory Nurse
  • Respiratory Physiotherapist
  • Clinical Respiratory Physiologist
  • Pulmonologist
  • Physician assistant
  • Respiratory Therapist




Market Analysis

The conference Pulmonary Disorders 2017 will be organized around the theme “Advanced Research and innovative Therapeutics Approaches towards Pulmonary Disorders”.

Our whole committee members are headed up for dazzling and enlightening scientific conference which includes lectures, speakers, symposia, workshops on different topics, poster presentations and various programs for participants from all around the world. We take immense pleasure inviting you to join us at Pulmonary Disorders 2017. You can have a world class experience with the eminent of this particular area. All members of Pulmonary Disorders 2017 organizing committee look forward in meeting you in Las Vegas, USA.

Importance and scope;
            A Pulmonary Disorders introduction, which defines the disease, including symptoms, diagnosis and treatment.
A detailed discussions on innovative and advance research towards pulmonary disorders, analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action.
The COPD, respiratory and Lungs clinical trial landscape analysis, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action.
An analysis of the COPD, Respiratory and Lungs marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, displayed as a heat map.

            An in-depth forecasting model for the COPD, respiratory and lungs market in Las Vegas, USA which considers the current marketed therapies, in addition to the potential market entry of new products. Discussion would include a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies. This takes into account worst and best case scenarios for market uptake, costs and patent expirations. Strategic consolidations within the COPD, pulmonary, respiratory and lungs clinical trial of Las Vegas indication are analysed.
An overview of the drivers and barriers for the COPD market is also included.

            The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

Despite recent patent expirations, including that of Advair Diskus (salmeterol/fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as that observed in other indications. This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition.

Although the COPD market is characterized by low diagnosis rates, campaigns to increase awareness of the disease in both patients and physicians has resulted in steadily rising diagnosis of COPD. Therefore, this has also contributed to market growth throughout the forecast period.

Why in Las Vegas, USA?

     With are of area of 352 km2, Las Vegas is a city in the United States, the most populous city in the state of Nevada, the county seat of Clark County, and the city proper of the Las Vegas Valley. The city bills itself as The Entertainment Capital of the World, and is the best place to let loose and have fun. Leave the world behind and immerse yourself in our endless entertainment options, world-famous restaurants, beautiful resorts and more shopping than you could do in a day. Las Vegas offers something to exceed your wildest expectations. A growing retirement and family city, Las Vegas is the 29th-most populous city in the United States, with a population of 603,488 at the 2013 United States Census Estimates. And, add a less-than-desirable ranking to Las Vegas’ portfolio: Las Vegas is in  top-10 ranking among the most polluted cities in the United States.

     The American Lung Association in its annual “State of the Air” report, released today, gave Las Vegas-Henderson a failing grade and ranked it as the 10th worst among 277 metropolitan areas in the country for ozone pollution.

The report found that while the valley’s high-ozone days had fallen significantly since 1996, the 19.7 high-ozone days measured were well above the “safe” standard of four days annually.

     Los Angeles-Long Beach, with 121.8 high-ozone days, topped the list for the nation’s worst pollution. In all, six California metropolitan areas were in the top 10. The report said half of Americans live in counties where ozone or particle pollutions levels make the air unhealthy to breathe.

     The 15th annual national report card said while the nation overall continued to reduce particle pollution, poor air quality remains a significant public health concern. The report said ozone levels were much worse than in its 2013 report.

     Those most at-risk from ozone pollution are infants, children, teenagers and older adults; anyone with lung diseases like asthma or COPD; and people with heart disease or diabetes.

     The issue of adverse health effects of ambient air pollution has been extensively studied and reported worldwide over the past two decades in Las Vegas. The urban area of Reno and Sparks in northern Nevada is one of two major urban centers in Nevada; the other is Las Vegas. The northern area, which has undergone a rapid population growth in the last decade, has special geographic characteristics and air pollution patterns.

     The American Lung Association’s 2016 “State of the Air” report found Las Vegas ranked as the 60th-most polluted city in the nation for year-round particle pollution. Compared to the 2015 report, Las Vegas has seen an increase in year-round particles. This is in spite of a trend seen across the nation of lower particle pollution levels.

“The 2016 ‘State of the Air’ report finds unhealthful levels of ozone in Las Vegas, putting our local citizens at risk for premature death and other serious health effects such as asthma attacks and cardiovascular harm. And, since we have such high levels of year-round particle pollution, our citizens face increased risk for lung cancer,” said Kristina Crawford, Executive Director of the American Lung Association in Nevada - Las Vegas. “Across the nation, the report found continued improvement in air quality, but more than half of the people in the United States live in counties that have unhealthful levels of either ozone or particle pollution.”

     Each year the “State of the Air” reports on the two most widespread outdoor air pollutants, ozone pollution and particle pollution. The report analyzes particle pollution in two ways: through average annual particle pollution levels and short-term spikes in particle pollution. Both ozone and particle pollution are dangerous to public health and can be lethal. But the trends reported in this year’s report, which covers data collected in 2012-2014, are strikingly different for these pollutants nationwide, and also in Las Vegas.

A good news of for Las Vegas is that, compared to the 2015 report (2011-2013), Las Vegas experienced fewer unhealthy days of high ozone in this year’s report  of this year.

The 2016 report also found year-round particle pollution (soot) levels in 2012-2014 slightly higher than the 2015 report. Nationwide, the best progress in this year’s report came in reducing year-round levels of particle pollution.

       The 2016 report also tracked short-term spikes in particle pollution, as these can be extremely dangerous and even lethal. According to the 2016 report, Las Vegas has more days when short-term particle pollution has reached unhealthy levels in 2012-2014. This is in keeping with a trend seen across the nation of short-term spikes in particle pollution. Thus, the above parameters directly influence the pulmonary, respiratory lungs disease in Nevada USA. The graphic below presents the Top 10 leading causes of death in Nevada between 2000 and 2008, ranked by the percentage of all deaths due to that cause. Heart disease is the leading cause of death in both the United States and Nevada, accounting for over a quarter of all deaths in the Silver State. Cancer also contributes to a large percentage of deaths in the U.S. and Nevada (22.6%). Estimates are that cancer has led to over 4 million years of lost life in the U.S.3 Diabetes, although a relatively less prevalent cause of death in Nevada (1.8%) is an indicator of and contributor to both heart disease and cancer deaths. It shown in figure as below;



            The incidence, morbidity and mortality of chronic obstructive pulmonary disease (COPD) are rising throughout the world. The total economic cost of COPD in the US in 1993 was estimated to be over $US15.5 billion, with $US6.1 billion for hospitalisation, $US4.4 billion for physician and other fees, $US2.5 billion for drugs, $US1.5 billion for nursing home care and $US1.0 billion for home care. Office visits, hospital outpatient visits and emergency department visits accounted for 17.3% of the direct costs for COPD in the US. When stratified by severity, COPD treatment costs strongly correlate with disease severity.

       The American Thoracic Society, the European Respiratory Society and the British Thoracic Society have developed guidelines for the pharmacological treatment of COPD. However, the guidelines establish inhaled bronchodilators (anticholinergic agents and beta 2-adrenergic agonists) as the mainstay of therapy for patients with COPD. The guidelines were not based on cost analyses and thus are not a priori cost-effective guidelines. Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). Both products are effective bronchodilators in COPD.

       The purpose of this report is to place these new agents in an updated pharmacological guideline scheme, utilising recently published data on clinical efficacy as well as pharmacoeconomics. The annualised healthcare costs were computed to be $US788/patient/year for the combination ipratropium/salbutamol inhaler and $US1059/patient/year for salmeterol (1999 values). Based upon an improved understanding of the complexity of COPD, the response of patients to newer bronchodilators (given individually or in combination), and recent pharmacoeconomic data for COPD treatment, a new treatment algorithm with associated costs is proposed. The use of an algorithm, based on medical and pharmacoeconomic data, will improve lung function in patients with COPD, improve patient satisfaction (e.g. quality of life, dyspnoea) and outcomes (e.g. exacerbations).

       Lung cancer is by far the most common cause of cancer death in Nevada, killing almost 50 out of every 100,000 people in Nevada in 2008. About 31% of cancer deaths among men and 26% among women are from lung cancer. Lung cancer deaths have historically been higher among whites, while rates have been lowest among Hispanics and Asians.

Nevada Lung Cancer Mortality Trends:



The above clearly indicates that there is a need of the more numbers of Physicians of Pulmonary Associates, involved in advance research and medical education. There is a need of serious talk and discussions on this particular area to know the depth of its severity and solution to eradicate the related diseases.

List of approved drugs for the Pulmonary and respiratory diseases in USA;

Drugs Approved in 2016

1.  Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic obstructive pulmonary disease, Approved April 2016

2.  Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016

Drugs Approved in 2015

1. Alecensa (alectinib); Roche; For the treatment of ALK-positive, metastatic non-small cell lung cancer , Approved December 2015

2. Keytruda (pembrolizumab); Merck; For the treatment of PD-L1 positive advanced non-small cell lung cancer, Approved October 2015

3. Nucala (mepolizumab); GlaxoSmithKline; For the treatment of severe asthma with an eosinophilic phenotype, Approved November 2015

4. Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of metastatic squamous non-small cell lung cancer, Approved March 2015

5. Orkambi (lumacaftor and ivacaftor); Vertex Pharmaceuticals; For the treatment of cystic fibrosis, Approved July 2015

6. Portrazza (necitumumab) ; Eli Lilly; For the treatment of metastatic squamous non-small cell lung cancer, Approved November 2015

7. Stiolto Respimat (tiotropium bromide and olodaterol) ; Boehringer Ingelheim; For the maintenance of chronic obstructive pulmonary disease, Approved May 2015

8. Tagrisso (osimertinib); AstraZeneca; For the treatment of EGFR T790M mutation positive non-small cell lung cancer , Approved November 2015

9. Utibron Neohaler (indacaterol and glycopyrrolate); Novartis; For the long term, maintenance treatment of airflow obstruction in patients with COPD, Approved October 2015

Drugs Approved in 2014

1. Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline; For the treatment of asthma, Approved August 2014

2. Esbriet (pirfenidone); InterMune; For the treatment of idiopathic pulmonary fibrosis , Approved October 2014

3. Grastek (Timothy Grass Pollen Allergen Extract); Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014

4. Incruse Ellipta (umeclidinium inhalation powder); GlaxoSmithKline; For the treatment of chronic obstructive pulmonary disease, Approved May 2014

5. Ofev (nintedanib); Boehringer Ingelheim; For the treatment of idiopathic pulmonary fibrosis , Approved October 2014

6. Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014

7. Ragwitek (Short Ragweed Pollen Allergen Extract); Merck; For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014

8. Striverdi Respimat (olodaterol); Boehringer Ingelheim; For the treatment of chronic obstructive pulmonary disease , Approved July 2014

9. Zykadia (ceritinib); Novartis; For the treatment of ALK+ metastatic non-small cell lung cancer, Approved April 2014

Drugs Approved in 2013

1. Adempas (riociguat); Bayer Healthcare Pharmaceuticals; For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013

2. Anoro Ellipta (umeclidinium and vilanterol inhalation powder); GlaxoSmithKline; For the maintenance treatment of chronic obstructive pulmonary disease, Approved December of 2013

3. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder); GlaxoSmithKline; For the treatment of chronic obstructive pulmonary disease, Approved May 2013

4. Opsumit (macitentan); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved October 2013

5. Vibativ (telavancin); Theravance; For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus, Approved June 2013

List of Medical research centres in USA.
 

  1. Academy of Neuroscience for Architecture
  2. AIDS Research Alliance
  3. Alfred E. Mann Institute for Biomedical Engineering
  4. American College of Rheumatology Research and Education Foundation
  5. American College of Surgeons Oncology Group
  6. American Roentgen Ray Society
  7. Athinoula A. Martinos Center for Biomedical Imaging
  8.  
  9. Dana–Farber Cancer Institute
  10. Dana–Farber/Harvard Cancer Center
  11. Duke Cancer Institute
  12. Duke University Human Vaccine Institute
  13.  
  14. Eastern Cooperative Oncology Group
  15. Emerging Pathogens Institute
  16. Epilepsy Foundation of Florida University
  17. Eppley Institute for Research in Cancer and Allied Diseases
  18. Fred Hutchinson Cancer Research Center
  19.  
  20. Galveston National Laboratory
  21. Ganogen Research Institute
  22. Genetics Society of America
  23. George Washington University School of Medicine & Health Sciences
  24. Gladstone Institutes
  25. Gottlieb Institute
  26.  
  27. Hauptman-Woodward Medical Research Institute
  28. Henry M. Jackson Foundation for the Advancement of Military Medicine
  29. Hormel Institute
  30. House Ear Institute
  31. Howard Hughes Medical Institute
  32. Huntington Medical Research Institutes
  33. Huntsman Cancer Foundation
  34. Huntsman Cancer Institute
  35.  
  36. The Biodesign Institute
  37. Torrey Pines Institute for Molecular Studies
  38. Tower Cancer Research Foundation
  39.  
  40. University of Central Florida College of Medicine
  41. University of South Florida College of Medicine
  42. USC Norris Comprehensive Cancer Center
  43. USF Health Byrd Alzheimer's Institute
  1. Beckman Research Institute
  2. Bone Disease Program of Texas
  3. The Bonnie J. Addario a Breath Away from the Cure Foundation
  4. Boonshoft School of Medicine
  5. Brain Injury Research Institute
  6. Buck Institute for Research on Aging
  7.  
  8. Institute for Health Metrics and Evaluation
  9. Institute of Biosciences and Technology
  10. Institute of Gerontology
  11.  
  12. Jackson Laboratory
  13. John Paul II Medical Research Institute
  14. Kenneth S. Warren Institute
  15.  
  16. La Jolla Institute for Allergy and Immunology
  17. Lahey Hospital & Medical Center
  18. Lieber Institute for Brain Development
  19. Linus Pauling Institute
  20. Lovelace Respiratory Research Institute
  21.  
  22. Markey Cancer Center
  23. Memorial Sloan Kettering Cancer Center
  24. The Mind Research Network
  25. H. Lee Moffitt Cancer Center & Research Institute
  26. Myelin Repair Foundation
  27.  
  28. National Center for Biotechnology Information
  29. National Center for Integrative Biomedical Informatics
  30. National Comprehensive Cancer Network
  31. National Space Biomedical Research Institute
  32. National Wilms Tumor Study Group
  33. The Neurosciences Institute
  34. Nevada Cancer Institute
  35. New York Blood Center
  36. Nicholas Institute of Sports Medicine and Athletic Trauma
  37. Norris Cotton Cancer Center
  38.  
  39. Van Andel Institute
  40.  
  41. Winship Cancer Institute
  42.  
  43. Yale Cancer Center
  44. Yerkes National Primate Research Center
  45.  
  46. Zilkha Neurogenetic Institute
  47. UW Carbone Cancer Center
  1. California Institute for Regenerative Medicine
  2. California National Primate Research Center
  3. Cancer and Leukemia Group B
  4. Cancer Therapy & Research Center
  5. Center for Biologics Evaluation and Research
  6. Center for Cell and Gene Therapy
  7. Center for Disease Dynamics, Economics & Policy
  8. Center for Infectious Disease Research
  9. Center for Neural Science
  10. Center for the Study of Traumatic Encephalopathy
  11. Centers for Disease Control and Prevention
  12. The Christopher and Dana Reeve Paralysis Resource Center
  13. City of Hope National Medical Center
  14. Cleveland Clinic Lerner Research Institute
  15. Collaborative Study On The Genetics of Alcoholism
  16. Community Programs for Clinical Research on AIDS
  17. CONRAD (organization)
  18. Coriell Institute for Medical Research
  19.  
  20. Pacific Northwest Diabetes Research Institute
  21. Patient-Centered Outcomes Research Institute
  22. Pediatric Cancer Research Foundation
  23. Pritzker Neuropsychiatric Disorders Research Consortium
  24.  
  25. Office of Cancer Complementary and Alternative Medicine
  26.  
  27. Quality Assurance Review Center
  28.  
  29. Rice Center for Neuroengineering
  30. Roswell Park Cancer Institute
  31.  
  32. St. Jude Children's Research Hospital
  33. Salk Institute for Biological Studies
  34. Sanford Burnham Prebys Medical Discovery Institute
  35. Sarah Cannon Research Institute
  36. Scripps Research Institute
  37. Seattle Children's Research Institute
  38. Semel Institute for Neuroscience and Human Behavior
  39. SWOG

 

  1.  Pulmonary Disorders
  2. Symptoms of Pulmonary Disorders
  3. Pulmonary Function Testing and Diagnosis
  4. Acute Bronchitis
  5. Asthma and Related Disorders
  6. Bronchiectasis and Atelectasis
  7. COPD and Related Disorders
  8. Pulmonary Vascular Disease
  9. Diffuse Alveolar Hemorrhage
  10. Environmental Pulmonary Diseases
  11. Lung Diseases
  12. Pleural Effusion
  13. Pulmonary Embolism
  14. Sleep Apnea
  15. Pulmonary Research
  16. Pulmonary Rehabilitation
  17. Novel Approach and Therapies
     

There about 22 research centres in North America for the research and treatment of pulmonary and other respiratory related diseases.

  1. Over the course of the seven years of the study, 22 research centers around the North American countries, enrolled and treated participants. Thirteen centers participated for the majority of the active project, and participants from these centers comprise 90 percent of the total number enrolled.
  2. Baylor College of Medicine; Houston, TX Principal Investigator, Lauren B. Marangell, MD
  3. Case Western Reserve University; Cleveland, OH Principal Investigator, Joseph R. Calabrese, MD
  4. University of Colorado Health Sciences Center; Denver, CO Principal Investigator, Michael Allen, MD
  5. University of Louisville School of Medicine; Louisville, KY Principal Investigator, Rif El-Mallakh, MD
  6. Massachusetts General Hospital and Harvard School of Medicine; Boston, MA Principal Investigator, Andrew A. Nierenberg, MD
  7. University of Massachusetts Medical School; Worcester, MA Principal Investigator, Jayendra Patel, MD
  8. University of Missouri School of Medicine; Kansas City, MO Principal Investigator, Kemal Sagduyu, MD
  9. University of Oklahoma College of Medicine - Tulsa; Tulsa, OK Principal Investigator, Mark D. Fossey, MD
  10. University of Pennsylvania School of Medicine and Medical Center; Philadelphia, PA Principal Investigator, Laszlo Gyulai, MD
  11. University of Pittsburgh Western Psychiatric Institute and Clinic; Pittsburgh, PA Principal Investigator, Michael E. Thase, MD
  12. Portland Veteran’s Administration Medical Center; Portland, OR Principal Investigator, Peter Hauser, MD
  13. Stanford University School of Medicine; Stanford, CA Principal Investigator, Terence A. Ketter, MD
  14. University of Texas Health Science Center at San Antonio, San Antonio, TX Principal Investigator, Charles Bowden, MD

    Additional centres involved involves in respiratory education are: Howard University, Washington DC; Rush-Presbyterian St. Luke’s Medical Center, Chicago, IL; State University of New York at Buffalo, Buffalo, NY; Weill Medical College of Cornell University and New York Presbyterian Hospital, NY, NY; New York University School of Medicine, NY, NY; University of California San Diego, La Jolla, CA; University of Arizona, Tucson, AZ; and Medical University of South Carolina, Charleston, SC.

Major Associations around the Globe for Pulmonary and Respiratory Diseases.

  1. Alabama Society for Respiratory Care
  2. Alaska Society for Respiratory Care
  3. Associazione Scientifica Interdisciplinare per lo Studio delle Malattie Respiratorie (AIMAR) (Italy)
  4. Associazione Italiana Pneumologi Ospedalieri (AIPO) (Italy)
  5. American Association for Respiratory Care (AARC) (United States)
  6. American College of Chest Physicians (ACCP) (United States)
  7. American Thoracic Society (ATS) (United States)
  8. Asian Pacific Society of Respirology (APSR)
  9. Asociación Argentina de Medicina Respiratoria (Argentina)
  10. Associación Latin Americana del Tórax (ALAT)
  11. Austrian Society of Pneumology (ASP) (Austria)
  12. Belgian Thoracic Society
  13. Brazilian Thoracic Society
  14. British Thoracic Society
  15. Bulgarian Society of Respiratory Diseases
  16. California Society for Respiratory Care
  17. Canadian Society for Respiratory Therapy
  18. Canadian Thoracic Society
  19. Croatian Respiratory Society
  20. Colorado Society for Respiratory Care
  21. Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (Germany)
  22. Dutch Thoracic Society (NVALT)
  23. European Respiratory Society (ERS)
  24. Egyptian Society of Chest Diseases and Tuberculosis
  25. European Society of Thoracic Imaging (ESTI)
  26. Estonian Respiratory Society
  27. European Academy of Allergology and Clinical Immunology (EAACI)
  28. European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)
  29. European Lung Foundation (ELF) ( World Spirometry Day (WSD) )
  30. Global Smoke Free Partnership (GSP)
  31. Hellenic Thoracic Society (Greece)
  32. Hungarian Respiratory Society
  33. Indian Chest Society
  34. International Society for Aerosolin Medicine (ISAM)
  35. Irish Thoracic Society
  36. Kazakhstan National Respiratory Society (Kazakhstan)
  37. Kyrgyz Thoracic Society
  38. Latvian Society of Lung Physicians
  39. Lebanese Pulmonary Society
  40. Médecins sans frontières (MSF) (Doctors Without Borders)
  41. Moroccan Society of Allergy and Clinical Immunology
  42. National Research Institute of Tuberculosis and Lung Disease (Iran)
  43. National Board for Respiratory Care (NBRC)
  44. Pakistan Chest Society
  45. Pan African Thoracic Society (PATS)
  46. Polish Respiratory Society
  47. Primary Care Respiratory Journal (PCRJ)
  48. Romanian Society of Pneumology
  49. Russian Respiratory Society
  50. Saudi Thoracic Society
  51. Schweizerische Gesellschaft für Pneumologie (Switzerland)
  52. Slovak Pneumological and Ftiseological Society
  53. Slovenian Respiratory Society
  54. Sociedad Chilena de Enfermedades Respiratorias (Chile)
  55. Sociedad Española de Neumología y Cirugía Torácica (Spain)
  56. Sociedade Portuguesa de Pneumologia (Portugal)
  57. Société Algérienne de Pneumophtisiologie (Algeria)
  58. Société de Pneumologie de Langue Française (SPLF)
  59. Society of Albanian Pulmonologists
  60. South African Thoracic Society
  61. Taiwan Society of Pulmonary and Critical Care Medicine
  62. Texas Society for Respiratory Care
  63. The European Association for Cardio-Thoracic Surgery (EACTS)
  64. The Finnish Respiratory Society
  65. The Japanese Respiratory Society
  66. Tunisian Society of Respiratory Disease and Allergology
  67. Turkish Respiratory Society
  68. Turkish Thoracic Society


Target Audience:

  1. Respiratory Therapist
  2. Respiratory practitioner
  3. Respiratory Care Practitioner (RCP)
  4. Respiratory scientist
  5. Respiratory Nurse
  6. Respiratory Physiotherapist
  7. Clinical Respiratory Physiologist
  8. Pulmonologist
  9. Physician assistant


Current Status of Respiratory Drug Market in USA.

The respiratory drugs market in the Americas is likely to exceed USD 36 billion by 2020, growing at a CAGR of over 5%. The Americas accounted for 55.5% of the overall market share in 2015, with the US being the major revenue contributor.

However, there are opportunities such as the expansion of immunotherapy in emerging markets such as Brazil and Mexico. In addition, the launch of new disease-modifying therapies will prove to be a major factor driving the market growth in this region.

EMEA: increased awareness about respiratory diseases to boost growth

EMEA accounted for 27% of the global respiratory drugs market share in 2015. The market in EMEA is dominated by the UK, Germany, France, Italy, and Spain. Growing older adult population and focus on combination therapies are driving the market growth in this region.

The respiratory drugs market in EMEA is likely to exceed USD 18 billion by 2020, growing at a CAGR of over 6%. The market in EMEA is likely to grow at a moderate pace during the forecast period driven by increased awareness about respiratory diseases and cost-effective over-the-counter (OTC) drugs.

APAC: fastest growing market for respiratory drugs

The respiratory drugs market in APAC is expected to exceed USD 14 billion by 2020, growing at a CAGR of over 10%. APAC accounted for 17.5% of the global respiratory drugs market in 2015. The market in APAC is expected to grow rapidly as compared to the other regions due to increasing healthcare spending in this region. Japan, India, and China are the major revenue contributors to the market in this region. India and China together form the most lucrative markets in APAC because of their rapid economic growth.

As per the latest report, there are significant growth opportunities in countries such as China, Japan, and India because of healthcare investments provided by the respective governments and increasing out-of-pocket expenditure by individuals. “However, the increasing use of complementary and alternative medicine (CAM) therapies to treat respiratory diseases may offset the market growth.

Some of the top vendors in the global respiratory drugs market highlighted in the report are:

AstraZeneca
Boehringer Ingelheim
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis


Cost of Respiratory and related Drugs in USA

Brand Names

Drug Class

Prices (in $) per pill/unit

amoxicillin

Penicillin Antibiotics

9

Keflex (cephalexin)

Cephalosporin Antibiotics

11

Cipro
(ciprofloxacin)

Quinolone Antibiotics

10

Sulfatrim


Antifolate / Sulfa Antibiotic Combinations

8

Zithromax (azithromycin)

Macrolide Antibiotics

10

Bactrim

Antifolate

8

Septra

Antifolate

8

Augmentin

Penicillin Antibiotic / Beta Lactamase Inhibitor Combinations

18

Flagyl

Nitroimidazole Antibiotics

11

 

Likewise, there are more number of medicine with less popularity

Vibramycin 
(doxycycline hyclate)   Tetracycline Antibiotics   $33   |
DOXYCYCLINE is a tetracycline antibiotic. It kills certain bacteria or stops their growth. It is used to treat many kinds of infections, like dental, skin, respiratory, and urinary tract infections. It also treats acne, Lyme disease, malaria, and certain sexually transmitted infections.

Vibramycin Monohydrate
(doxycycline monohydrate)   Tetracycline Antibiotics   $35

Monodox
(doxycycline monohydrate)   Tetracycline Antibiotics   $35

Levaquin(levofloxacin)   Quinolone Antibiotics   $10  
Levaquin (levofloxacin) is a quinolone antibiotic similar to ciprofloxacin (Cipro), used to treat bacterial infections. Levofloxacin is considered a first-line treatment for urinary tract infections and is also used for sinusitis, bronchitis and pneumonia. Levofloxacin is taken once a day, compared to ciprofloxacin which is twice a day. It is available as generic levofloxacin.

Cefdinir   Cephalosporin Antibiotics   $26  
CEFDINIR is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Dynacin
(minocycline)   Tetracycline Antibiotics   $195
MINOCYCLINE is a tetracycline antibiotic. It stops the growth of some bacteria. It is used to treat many kinds of infections, like acne, respiratory, urinary tract, and sexually transmitted infections. It will not work for colds, flu, or other viral infections.

Minocin(minocycline)   Tetracycline Antibiotics   $195
MINOCYCLINE is a tetracycline antibiotic. It stops the growth of some bacteria. It is used to treat many kinds of infections, like acne, respiratory, urinary tract, and sexually transmitted infections. It will not work for colds, flu, or other viral infections.

Ofloxacin   Quinolone Antibiotics   $13
OFLOXACIN is a quinolone antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Erythromycin   Macrolide Antibiotics   $26
ERYTHROMYCIN is a macrolide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Ceftin(cefuroxime axetil)   Cephalosporin Antibiotics   $53
CEFUROXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Biaxin(clarithromycin)   Macrolide Antibiotics   $22
CLARITHROMYCIN is a macrolide antibiotic. It is used to treat or prevent certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Ampicillin   Penicillin Antibiotics   $15
AMPICILLIN is a penicillin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Cefprozil   Cephalosporin Antibiotics   $51
CEFPROZIL is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Avelox(moxifloxacin)   Quinolone Antibiotics   $91
MOXIFLOXACIN is a quinolone antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Tetracycline  Tetracycline Antibiotics   $363
TETRACYCLINE is a tetracycline antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Vancomycin   Glycopeptide Antibiotics   $293
VANCOMYCIN is a glycopeptide antibiotic. It is used to treat certain kinds of bacterial infections in the bowel. It will not work for colds, flu, or other viral infections.

Doryx
(doxycycline hyclate er)   Tetracycline Antibiotics   $139

DOXYCYCLINE is a tetracycline antibiotic. It is used to treat certain kinds of bacterial infections, Lyme disease, and malaria. It will not work for colds, flu, or other viral infections.

Ery-Tab   Macrolide Antibiotics   $381
ERYTHROMYCIN is a macrolide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Suprax
(cefixime)   Cephalosporin Antibiotics   $158
CEFIXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Clarithromycin ER   Macrolide Antibiotics   $77
CLARITHROMYCIN is a macrolide antibiotic. It is used to treat or prevent certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

E.E.S.(erythromycin ethylsuccinate)   Macrolide Antibiotics   $522
ERYTHROMYCIN is a macrolide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Eryped   Macrolide Antibiotics   $390
ERYTHROMYCIN is a macrolide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Rocephin
(ceftriaxone)   Cephalosporin Antibiotics  $9
CEFTRIAXONE is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Erythrocin   Macrolide Antibiotics   $501
ERYTHROMYCIN is a macrolide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Cefaclor   Cephalosporin Antibiotics   $67
CEFACLOR is an cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Acticlate   Tetracycline Antibiotics   $819
DOXYCYCLINE is a tetracycline antibiotic. It kills certain bacteria or stops their growth. It is used to treat many kinds of infections, like dental, skin, respiratory, and urinary tract infections. It also treats acne, Lyme disease, malaria, and certain sexually transmitted infections.

Erythromycin DR   Macrolide Antibiotics   $95
ERYTHROMYCIN is a macrolide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Vibramycin Calcium   Tetracycline Antibiotics   $51
DOXYCYCLINE is a tetracycline antibiotic. It kills certain bacteria or stops their growth. It is used to treat many kinds of infections, like dental, skin, respiratory, and urinary tract infections. It also treats acne, Lyme disease, malaria, and certain sexually transmitted infections.

Demeclocycline   Tetracycline Antibiotics  $ 467
DEMECLOCYCLINE is a tetracycline antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Cefazolin   Cephalosporin Antibiotics   $6
CEFAZOLIN is a cephalosprin antibiotic. It is used to treat or prevent certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Cedax
(ceftibuten)   Cephalosporin Antibiotics   $237
CEFTIBUTEN is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Morgidox   Tetracycline Antibiotics   $96
DOXYCYCLINE is a tetracycline antibiotic. It kills certain bacteria or stops their growth. It is used to treat many kinds of infections, like dental, skin, respiratory, and urinary tract infections. It also treats acne, Lyme disease, malaria, and certain sexually transmitted infections.

Factive   Quinolone Antibiotics   $216
GEMIFLOXACIN is a quinolone antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Spectracef   Cephalosporin Antibiotics   $440
CEFDITOREN is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Cefaclor ER   Cephalosporin Antibiotics   $275
CEFACLOR is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

Pce   Macrolide Antibiotics   $75

Virazole   Nucleoside Analogue Antivirals   $25,619
RIBAVIRIN is an antiviral medicine. It is used to treat severe respiratory syncytial virus (RSV) in hospitalized children.

Synagis   Monoclonal Antibodies   $1,443  
PALIVIZUMAB is an antibody. It is used in infants and children to prevent severe cases of respiratory syncytial virus (RSV) infection. Children treated with this medicine may still get RSV but will not get as sick as if they were not treated at all. This medicine does not protect against other infections.

Azactam
(aztreonam)   Monobactam Antibiotics  $ 65
Major advancement in treatment of Bipolar Disorder

Respiratory Care Devices Market worth 21.9 Billion USD by 2020
     The respiratory care devices market is growing at a significant rate since the last decade. Growth in this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidences of preterm births, and lifestyle changes. However, lack of awareness and harmful effects of certain respiratory care devices on neonates are the major challenges in this market.

     In this report, the respiratory care devices market is segmented on the basis of products and end users. On the basis of products, the respiratory care devices market is segmented into therapeutic devices, monitoring devices, diagnostic devices, and consumables & accessories. The therapeutic devices segment is further divided into humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, reusable resuscitators, ventilators, inhalers, masks, nitric oxide delivery units, and oxygen hoods. The monitoring devices segment is categorized into pulse oximeters, capnographs, and gas analyzers. The diagnostics devices segment is subdivided into spirometers, peak flow meters, polysomnography (PSG) devices, and other diagnostic devices; while, the consumables and accessories segment is categorized into disposable masks, disposable resuscitators, tracheostomy tubes, nasal cannulas, and other consumables & accessories.

     In 2014, the therapeutic devices segment accounted for the largest share of the global respiratory care devices market. The large share of this segment is mainly attributed to the rising adoption of various therapeutic devices such as nebulizers, oxygen concentrators, humidifiers, and PAP devices due to growth in the elderly population and rising prevalence of respiratory diseases.

On the basis of end users, the respiratory care devices market is bifurcated into hospitals and home care. Hospitals are the major end users of the global respiratory care devices market, owing to the financial capabilities of hospitals to purchase high-end instruments as well as the availability of trained professionals to operate respiratory care devices.

     On the basis of regions, the respiratory care devices market is broadly segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Highly developed healthcare systems and rising healthcare expenditures are the major factors responsible for the large shares of North America and Europe in the global respiratory care devices market. However, the Asia-Pacific region is expected to grow at the highest CAGR, owing to the presence of a large pool of respiratory patients, increasing healthcare expenditure, rapidly developing healthcare infrastructure, increasing per capita incomes, and growing middle-class population in emerging countries of this region.

     Major players in the global respiratory care devices market include Philips Healthcare (Netherlands), ResMed, Inc. (U.S.), Covidien plc (Ireland), Masimo Corporation (U.S.), Fisher and Paykel Healthcare Limited (New Zealand), and CareFusion Corporation (U.S.).

Pulmonary and related respiratory diseases;
Pulmonary Disease is very common. Approximately 12 million adults in the U.S. are diagnosed with pulmonary disease, and 120,000 die from it each year. An additional 12 million adults in the U.S. are thought to have undiagnosed pulmonary disease. Pulmonary Disease death rates for women have risen steadily. Today, more women than men die from pulmonary disease each year. Today, spirometry is widely available to doctors in primary care settings, facilitating earlier diagnosis of pulmonary disease. Doctors now recognize that nicotine addiction makes it very difficult for people to stop smoking. Fortunately, methods for smoking cessation have improved, and smokers can benefit from effective treatments and counseling to overcome nicotine addiction.

     A wide range of treatments are now available to improve the quality and length of life for pulmonary disease patients, including vaccinations against influenza and pneumonia, inhaled bronchodilator drugs, pulmonary rehabilitation, oxygen therapy, and surgical interventions. Glucocorticoids and antibiotics are regularly used to treat acute exacerbations of pulmonary disease.

     Several NIH-sponsored research programs have increased understanding of pulmonary disease and fostered new treatments. For example, the Nocturnal Oxygen Therapy Trial showed that some patients with advanced pulmonary disease live longer if given long-term oxygen therapy. The Lung Health Study showed that a smoking cessation intervention can improve long-term survival of Pulmonary Disease patients. The National Emphysema Treatment Trial (NETT) (http://www.nhlbi.nih.gov/health/prof/lung/nett/lvrsweb.htm) showed that lung-volume-reduction surgery can improve the quality and/or length of life in certain groups of patients with severe pulmonary disease. Although researchers continue to investigate the role of proteases in pulmonary disease, new findings suggest strong inflammatory and immune components to pulmonary disease. This insight led to a variety of new ideas about Pulmonary Disease treatment and has stimulated a surge in research activity.

Despite rapidly rising illness and death rates due to pulmonary disease, awareness of pulmonary disease among the general public and those at greatest risk for the disease remains low.

     To promote public awareness of pulmonary disease, the NIH is partnering with patient advocacy groups and health professional organizations on a pulmonary disease awareness and education campaign called pulmonary disease: Learn More, Breathe Better (http://www.nhlbi.nih.gov/health/public/lung/Pulmonary Disease/lmbb-campaign/index.htm). The campaign focuses on increasing knowledge of symptoms, diagnosis, and treatment among pulmonary disease patients and people at risk of developing pulmonary disease.

Future of Pulmonary and Respiratory related diseases.

     It is now recognized that 10-20% of pulmonary disease patients have never smoked! Furthermore, only a fraction of smokers develop pulmonary disease, suggesting that both genetic and environmental factors influence the risk of developing pulmonary disease. Investigators in the pulmonary disease gene Study will recruit 10,000 smokers and nonsmokers to identify the genetic factors that determine why some people develop pulmonary disease and others do not.

Pulmonary Disease is a complex disease that presents in many different ways. The NIH is supporting research to help tailor therapies for pulmonary disease to individual patients. A study called SPIROMICS (subpopulations and intermediate outcome measures in pulmonary disease study) will use genetic data, genomic information, and analyses of phenotypes and biomarkers to determine how pulmonary disease differentially affects patient subpopulations.

     The NIH pulmonary disease Clinical Research Network (CCRN) is performing therapeutic trials in patients with moderate to severe pulmonary disease, with an emphasis on preventing and managing exacerbations. One study is comparing the effectiveness of two different pneumococcal vaccines in patients with pulmonary disease. Another study will determine whether an antibiotic called azithromycin is useful in reducing the severity and number of exacerbations. In addition, statin drugs, best known for their use in lowering cholesterol, are being evaluated for their possible role in preventing or diminishing pulmonary disease exacerbations.

The NIH, in cooperation with the Centers for Medicare and Medicaid Services, is supporting the Long-Term Oxygen Treatment Trial (LOTT) to determine whether supplemental oxygen is beneficial to patients with milder disease than those studied previously. The NIH also supports the Lung Tissue Research Consortium (LTRC), which provides lung tissue specimens to qualified researchers investigating the biological basis of PULMONARY DISEASE and other lung diseases.

The NIH supports research to improve understanding of the disease process in pulmonary disease, identify pivotal points in its onset and progression, and provide the knowledge base needed to intervene early and prevent its development or progression.





Past Conference Report

Lung-2015

We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making Lung 2015 a wonderful event!

International Conference and Exhibition on Lung Disorders & Therapeutics was organized by Conference Series LLC, during July 13 15, 2015 in Baltimore, USA. We successfully hosted the event at the conference venue. Active participation and generous response were received from the Organizing Committee Members, Editorial Board Members of OMICS Group Journals, scientists, researchers, as well as experts from Lung Disorders and students from diverse groups who made this conference as one of the most successful and productive events in 2015 from OMICS Group. It is the world’s meeting that is dedicated to lung disorders and other thoracic malignancies.

The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.

The conference was initiated with a warm welcome note from Honourable guests and the Keynote forum lead by Dr. Janet M Urban Motivator Tobacco Treatment and Wellness Services, USA honourable Moderator for the conference.

Various sessions were carried out with multiple presentations from speakers all around the world. Major Sessions to be discussed were:

·         Lung and Metabolism

·         Lung Infections

·         Lung Disorders

·         Pulmonary Disease: Tuberculosis

·         Pulmonary Disease: Pneumonia

·         Lung Cancer and Treatment Strategies

·         Respiratory Tract and Associated Defence Mechanisms

·         Biological and Pathological Effects

·         Advanced Diagnostic Techniques for Lung Disorders

·         Prevention, Cure and Control Management of Lung Disorders

·         Novel and Futuristic Research Aspects and Clinical Trials

The conference witnessed an amalgamation of peerless speakers, who enlightened the crowd with their enviable research knowledge and on various alluring topics related to the field of lungs, carried out through various scientific sessions and plenary lectures:

Extracellular purines in lung endothelial barrier regulation Dr. Alexander D Verin Georgia Regents          University, USA

Airway Passages Narrowness and Pressure Oscillation Dr. Ahmed Al Jumaily, Auckland University of Technology, New Zealand

Smoking cessation: A review of the literature Dr. Janet M Urban, Motivator Tobacco Treatment and Wellness Services, USA

The role of necroptosis in the pathogenesis of lung injury following kidney transplant andbeyond Dr. Daqing Ma, Imperial College London, UK

TB or not TB that is the question Understanding and diagnosing TB using metabolomics Dr. Du Toit Loots, North West University, South Africa

With the unique feedbacks from the conference, Conference Series LLC announced the commencement of the International Conference on Pulmonary Disorders on April 20-21, 2017 at Las Vegas, USA. With the support and contribution of the Organizing Committee Members, we successfully hosted the Lung Disorders & Therapeutics 2015” at the conference venue. Hence, we look forward to see your benign presence with active contribution and support to make Pulmonary Disorders 2017 successful once more.

Let us meet again @ Pulmonary Disorders 2017


Past Reports  Gallery  



Past Conference Report

Pathology-2014

The 3rd International Conference and Exhibition on Pathology, organized by the OMICS Group was held on April 14-15, 2014 at San Antonio, USA. The conference was organized around the theme "Leading edge technology, techniques and current advances in the field of pathology" which comprised of 15 Tracks designed to offer comprehensive sessions that address current issues in the field of Pathology. This annual conference brought together eminent scientists from across 20 countries in which many critical issues were discussed in depth to provide up-to-date information to the world. On the other hand, the meeting provided an opportunity for an open and animated sharing of ideas and experiences.

The conference was initiated with a series of keynote addresses by well-known speakers Jianhua Luo, University of Pittsburgh School of Medicine, USA, Bogdan Czerniak, UT MD Anderson Cancer Center, USA, Rajat Sethi, California Health Sciences University, USA, Rui-An Wang, The Fourth Military Medical University, China, who gave their energetic and fruitful contributions at Pathology-2013.

OMICS Group will acknowledge with gratitude the support by all the Editorial Board Members of Journal of Clinical & Experimental Pathology and Journal of Plant Pathology & Microbiology for their valuable suggestions for up growth of the Organization. 

Pathology-2014 could be an exceptional event that brings along a novel and International mixture of giant and medium pathology analysis, leading universities and pathology analysis establishments creating the conference an ideal platform to share expertise, foster collaborations across trade and world, and assess rising technologies across and the world. OMICS cluster invitations all the participants across the world to attend the 4th­ International Conference and Exhibition on Pathology throughout March 23-25, Chicago, USA.


Past Reports  Gallery  



Past Conference Report

Chemotherapy-2015

Over thousands of scholars from the field of Chemotherapy stepped away from their nations last Tuesday, August 2nd, 2015to take part in an ostentatious event “International Conference on Antimicrobial Agents and Chemotherapy” August 04-06, 2015, in Valencia, Spain. The conference was organized around a single theme “Emerging techniques and advancements in the field of chemotherapy” which comprised of 06 tracks with knowledge oriented presentations igniting young minds in the crowd.

The Conference provided a rostrum for interaction among keynotes, chair & co-chairs, plenary speakers, poster presentees, young research fellows & delegates and to share their experiences, ideas & research, thus helping to generate a new way of looking at Cancer treatments.

Conference began with the welcome message given by our moderator Dr. Emil Toma, University of Montreal, USA, followed by a Keynote series of well-known speakers:

  • Dr. Emil Toma, University of Montreal, USA.
  • Dr. Didier Coquoz, Copexis, Switzerland.
  • Dr. Hiroyuki Osada, RIKEN Center for Sustainable Resource Science, Japan.

The session was chaired by Dr. Emil Toma, University of Montreal, USA, preceded with paramount Oral Presentations. The Conference also witnessed an amalgamation of eminent speakers like:

  • Junjun Qiu, Obstetrics and Gynecology Hospital of Fudan University, China.
  • Helene Castel, Universite de Rouen, France
  • Paula Sabbo Bernado, Brazilian National Cancer Institute, Brazil.

The Conference also provided a platform for a grandiose Workshop by:

  • Isabel Portero Sanchez, Universidad Complutense & BIOHOPE Scientific Solutions, Spain
  • Dirk Buscher, Gri-Cel S.A. Spain
  • Eva Martin Becerra, Gradocell& IMMPULSO Medical Sciences, Spain

The second day session was chaired and Keynote speech was given by:

  • Dr. Hiroyuki Osada, RIKEN Center for Sustainable Resource Science, Japan

The session was preceded by Oral Presentations by:

  • Dr. Hiroyuki Osada, RIKEN Center for Sustainable Resource Science, Japan
  • Dr. Minoru Yoshida, RIKEN Center for Sustainable Resource Science, Japan
  • Natalia Martins, Polytechnic Institute of Braganca, Portugal

A Global Platform was given to students to explore their research work under the category Young Research Forum:

  • Bin Li, University of Hong Kong, China
  • Wen WenXu, University of Hong Kong, China
  • Natalia Martins, Polytechnic Institute of Braganca, Portugal
  • Maude Loignon, University of Montreal, Canada

OMICS International acknowledges all the Organizing Committee Members, Moderator, Chair and Editorial Board Members of OMICS group Journals, Speakers, Students, Delegates and Media Partners in making this event a great success. We are also obliged to various government authorities, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members, for their gracious presence, support and assistance.

After the immense and grand response received from Chemotherapy-2015, OMICS International proudly announces the 2nd International Conference on Antimicrobial Agents and Chemotherapy, June 04-06, 2016, Dallas, USA.

More information on Chemotherapy-2016


Past Reports  Gallery  



Past Conference Report

Addiction Therapy 2015

 

After the successful completion of our previous conferences, OMICS International hosted 4thInternational Conference and Exhibition on Addiction Research & Therapy during August 03-05, 2015 at Hyatt Regency Orlando International Airport, Orlando, Florida, USA.

The conference was organized around the theme “Accentuate knowledge and explore new treatment regimen for addiction” which covers a wide range of critically important sessions related to Addiction Research & Therapy. This annual conference brought together eminent scientists from more than 10 countries in which many critical issues were discussed in depth to provide au courant information to the world. On the other hand, the meeting was the best rostrum to share ideas and experiences and to report unique and unusual cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations. The three day program witnessed thought provoking keynote and plenary presentations from experts in the field of current research like Addiction Genetics, Drug addiction and Neuro Toxicology and their significance in clinical research and health diagnostics.

Addiction Therapy-2015 Organizing Committee would like to thank the Moderator of the conference, Dr. Adi Jaffe, Alternatives Behavioral Health, USA who contributed meticulously and exuberantly for the smooth functioning of this event.

The conference was initiated with a Keynote series of well-known speakers Dr. Jason Connor, The University of Queensland, Australia and Dr. Igor Elman, Harvard Medical School, USA followed by Dr. Kathy Sexton Radek, Elmhurst College, USA and it was followed by oral and poster presentations. The sessions were Chaired by Dr. Kathy Sexton Radek, Elmhurst College, Dr. Igor Elman, Harvard Medical School, USA and Dr. Barry Tolchard, University of New England, Australia and Co-chaired by Dr. Monika Heidemarie Seltenhammer, Medical University of Vienna, Austria.

Addiction Therapy 2015 Conference also witnessed a symposium by Dr. Prapapun Chucharoen, Mahidol University, Thailand along with Dr. Bang-on Thepthien, Mahidol University, Thailand on “Continuum of Care for Drug Addiction”. A special session by Dr.Renee Brown Next Level Recovery LLC., USA on “Treatment with real life in mind: A model where behavioral science shakes hands traditional recovery methodologies” and a workshop session by Dr. E Renea Snyder Pennsylvania Department of Corrections, USA about “AOD recovery units in correctional institutions”, kindled the lamp of knowledge in the crowd.

OMICS group wishes to acknowledge all the Organizing Committee Members, Moderator, Chair and Co-Chair, Editorial Board Members of OMICS group Journals, Speakers, Students and Delegates in making this event a grand success. We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. We are glad to inform that all accepted abstracts for the conference have been indexed in OMICS Group “Journal of Addiction Research & Therapy” as a special issue.

With the unique feedbacks from the conference, OMICS Group would like to announce the commencement of the "5th International Conference and Exhibition on Addiction Research & Therapy” to be held from October 06-08, 2016, Miami Florida, USA.


Past Reports  Gallery  



Key Topics

  • Absent Pulmonary Valve
  • Acute Bronchitis
  • Acute respiratory distress syndrome
  • Anomalous Left Coronary Artery
  • Aortic Stenosis
  • Aortopulmonary Window
  • Aspirin-exacerbated respiratory disease
  • Asthma and Related Disorders
  • Atrial Septal Defect
  • Atrioventricular Septal Defect, Complete
  • Atrioventricular Septal Defect, Partial
  • Bicuspid Aortic Valve
  • Bronchiectasis and Atelectasis
  • Chest Pain
  • Chronic obstructive pulmonary disease
  • Coarctation of the Aorta
  • COPD and Related Disorders
  • Coronary Artery Fistula
  • Dextrocardia
  • Diffuse Alveolar Hemorrhage
  • Dilated Cardiomyopathy
  • Double Aortic Arch
  • Double Inlet Left Ventricle
  • Double Outlet Right Ventricle
  • Ebstein's Anomaly
  • Eisenmenger Complex
  • Electrophysiology
  • Endocardial Cushion Defect
  • Environmental Pulmonary Diseases
  • Evaluation of wheezing illnesses other than asthma in adults
  • Extrapulmonary manifestations of sarcoidosis
  • Hypertension, Pulmonary
  • Hypertension, Systemic
  • Hypertrophic Cardiomyopathy
  • Hypoplastic Left Heart Syndrome
  • Image-guided bronchoscopy for biopsy of peripheral pulmonary lesions
  • Interrupted Aortic Arch
  • Kawasaki Disease
  • Lung Diseases
  • Marfan's Syndrome
  • Measurement of pleural pressure
  • Mitral Stenosis
  • Mitral Valve Prolapse
  • Myocarditis
  • Novel Approach and Therapies
  • Overview of the pulmonary complications of sickle cell disease
  • Partial Anomalous Pulmonary Venous Return
  • Patent Ductus Arteriosus
  • Patent Foramen Ovale
  • Pericarditis
  • Pleural Effusion
  • Primary ciliary dyskinesia (immotile-cilia syndrome)
  • Prone ventilation for adult patients with acute respiratory distress syndrome
  • Pulmonary Atresia
  • Pulmonary Disorders
  • Pulmonary Embolism
  • Pulmonary Function Testing and Diagnosis
  • Pulmonary Rehabilitation
  • Pulmonary Research
  • Pulmonary Stenosis
  • Pulmonary Vascular Disease
  • Rheumatic Fever - Acute
  • Sepsis syndromes in adults
  • Shone's Complex
  • Single Ventricle
  • Sleep Apnea
  • Symptoms of Pulmonary Disorders
  • Syncope
  • Tetralogy of Fallot
  • Thoracic ultrasound
  • Total Anomalous Pulmonary Venous Return
  • Transposition of the Great Arteries, D-Type
  • Transposition of the Great Arteries, L-Type
  • Treatment of pulmonary hypertension in adults
  • Tricuspid Atresia
  • Truncus Arteriosus
  • Vascular Ring
  • Venous thromboembolism
  • Ventricular Septal Defect

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date April 24 - 25, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations